Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cybin Inc (NY: CYBN )

10.78 UNCHANGED
Streaming Delayed Price Updated: 8:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
38 39 Next >
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO to Participate at Upcoming Milken Institute Global Conference
Via Investor Brand Network
Cybin to Participate at the 26th Annual Milken Institute Global Conference
From Cybin Inc.
Via Business Wire
Seelos Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today
Via Benzinga
Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today
Via Benzinga
Cybin, Mind Medicine Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From April 18, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From April 17, 2023
Via Benzinga
Psyched: Clinical-Grade MDMA, LSD For Depression, Partnerships For Delivering Psychedelic Therapies & More
Revolutionizing Psychedelics: 2 Industry Leaders Team Up On Clinical-Grade MDMA Capsules 
Via Benzinga
ATAI Life Sciences, Seelos Therapeutics Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From April 13, 2023
Via Benzinga
EXCLUSIVE: Investing In The Unique Growth Market Of Psychedelics
The global psychedelics market of drugs such as psilocybin, ketamine and LSD is booming and there are plenty of ways to get involved in the space. 
Via Benzinga
Cybin Offers Free Online Training To Facilitate Psychedelic Therapy
Cybin Inc. (NYSE: CYBN), a clinical-stage biopharma company developing innovative psychedelic-based treatment options, is launching a free online facilitation training course. 
Via Benzinga
Psychedelic Stock Gainers And Losers From April 12, 2023
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Launches EMBARK OA, a Cost-Free Facilitator Training Program for Psychedelic Therapy
Via Investor Brand Network
Cybin Announces EMBARK Open Access, the First Free Online Course Providing Facilitator Training for Psychedelic Therapy
From Cybin Inc.
Via Business Wire
Psychedelic Stock Gainers And Losers From April 11, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From April 10, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From April 7, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From April 6, 2023
Via Benzinga
Compass Pathways, GH Research Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From April 4, 2023
Via Benzinga
"Multi-Bagger" Portfolio Down 13% In March; Still Up Almost 6% YTD
The 
Via Talk Markets
Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelics For Major Depressive Disorder And Anxiety Disorders: Data Suggests Cybin's Deuterated Analogs Could Work
Cybin Inc (NYSE: CYBN) recently provided updates on its innovative treatments for Major Depressive Disorder (MDD) and Anxiety Disorders during its Investor Day. 
Via Benzinga
Largest Psychedelic Stocks -3.4% In March
The munKNEE Psychedelic Drug Stocks Index was down 3.4% in March but is still +1.2% YTD. The best news is the continuing high price targets being set by analysts. 
Via Talk Markets
Psychedelic Stock Gainers And Losers From March 31, 2023
Via Benzinga
Seelos Therapeutics, Mind Medicine Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From March 29, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From March 28, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From March 27, 2023
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
38 39 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.